内科

目的探讨参松养心胶囊联合胺碘酮治疗对阵发性房颤患者血清基质金属蛋白酶2（MMP-2）、高敏C反应蛋白（hs-CRP）水平的影响。方法选取2014年4月至2015年7月我院收治的阵发性房颤患者90例为研究对象，随机分为观察组和对照组，每组45例。在基础治疗的同时，对照组患者加用胺碘酮治疗，观察组患者加用胺碘酮以及参松养心胶囊治疗，比较两组患者的临床疗效及血清MMP-2、hs-CRP水平。结果治疗1个月，观察组患者的治疗总有效率为95.55%，对照组为77.78%，两组比较差异有统计学意义（P＜0.05）；秩和检验结果显示，观察组患者的临床疗效优于对照组（P＜0.05）。治疗后观察组患者的左心房内径显著下降（P＜0.05），两组患者左心室射血分数显著上升（P＜0.05），观察组患者左心房内径及左心室射血分数均显著优于对照组（P＜0.01）。治疗后两组患者的hs-CRP、MMP-2水平均显著下降（P＜0.05），治疗时间越长其下降幅度越大；治疗1个月后观察组患者hs-CRP显著低于对照组（P＜0.05）。随访3个月，观察组患者阵发性房颤平均发生次数显著少于对照组（P＜0.05）。结论参松养心胶囊联合胺碘酮治疗能够显著降低阵发性房颤患者血清MMP-2和hs-CRP水平，改善心房重构，临床治疗效果显著，值得推广应用。

ObjectiveTo explore the effect of Shensongyangxin capsules combined with amiodarone on MMP-2 and hs-CRP of patients with paroxysmal atrial fibrillation. MethodsA total of 90 patients with paroxysmal atrial fibrillation admitted to our hospital from April 2014 to July 2015 were randomly divided into observation group and control group, with 45 cases in each group. Patients in the two groups were treated with foundation treatment, on the basis of foundation treatment, the control group was treated with amiodarone, while the observation group received amiodarone combined with Shensongyangxin capsules, the levels of MMP-2 and hs-CRP, clinical effects were compared between the two groups. ResultsAfter one month of treatment, the total effective rate in the observation group was 77.78%, which was significantly higher than that in the control group (77.78%), and rank-sum test show that the clinical effect in the observation group was significantly superior to that in the control group (P＜0.05).After treatment, the left ventricular ejection fraction in the two groups were significantly increased compared with those before treatment, and the increased in the observation group was more significant (P＜0.05), the left atrial diameter in the observation group was significantly decreased compared with that before treatment, which was also shorter than that in the control group (P＜0.01). After treatment, the levels of hs-CRP and MMP-2 in the two groups were significantly decreased compared with those before treatment, and as the treatment progressed, the decreased was more significant; after one month of treatment, the level of hs-CRP in the observation group was significantly lower than that in the control group (P＜0.005). Followed up for 3 months, the average number of atrial fibrillation recurrence in the observation group was significantly less than that in the control group (P＜0.05). ConclusionsShensongyangxin capsules combined with amiodarone can reduce the levels of serum MMP-2 and hs-CRP in patients with paroxysmal atrial fibrillation, and improve the atrial remodeling,which is worthy of popularization and application.